We provide you with 20 years of free, institutional-grade data for NRIX stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of NRIX. Explore the full financial landscape of NRIX stock.
| Reported Date | CIK | Ticker | Type |
|---|
Nurix Therapeutics, Inc(NASDAQ:NRIX) 
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader with immunomodul...
Website: http://www.nurixtx.com
Founded: 2009
Full Time Employees: 122
CEO: Arthur T. Sands
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report about NRIX stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.